Clinical trial
Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight…
NCT00450645 · Azienda Ospedaliera Universitaria Policlinico, Other · Unknown status
Key facts
| NCT number | NCT00450645 |
|---|---|
| Title | Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis |
| Official title | Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs |
| Acronym | Cancer-DACUS |
| Lead sponsor | Azienda Ospedaliera Universitaria Policlinico, Other |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Deep Vein Thrombosis, Cancer |
| Intervention type | Drug |
| Interventions | low molecular weight heparin |
| Enrollment | 300 |
| Start date | Mar 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2011 |
| First posted | Mar 22, 2007 |
| Last update posted | Mar 4, 2009 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: